NSAID-induced liver damage with cholestasis
-
Published:2021-10-02
Issue:23
Volume:
Page:37-48
-
ISSN:2078-5631
-
Container-title:Medical alphabet
-
language:
-
Short-container-title:Medicinskij alfavit
Author:
Pereverzev A. P.1ORCID, Ostroumova O. D.2ORCID, Golovina O. V.1ORCID, Filippova A. V.1ORCID, Pavleeva Е. Е.3ORCID
Affiliation:
1. Russian Medical Academy for Continuing Professional Education 2. Russian Medical Academy for Continuing Professional Education; I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) 3. Moscow State University of Medicine and Dentistry n. a. A. I. Evdokimov
Abstract
he liver is one of the organs most often affected by medication (MP) intake. Drug-induced liver damage with cholestasis (LIPCH), on the one hand, rarely leads to death in comparison with the hepatocellular type, but, on the other hand, is more often characterized by a long, in some cases chronic course. This type of liver damage is characterized by an increase in the activity of alkaline phosphatase (ALP) > 2 upper limits of normal (ULN) or the ratio of alanine aminotransferase (ALT) / ALP < 2 in chronic course. Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most readily available (including over-the-counter) and widely used drugs in clinical practice and are often the cause of LIPCH. This article summarizes the available data at the time of preparation of the article on the prevalence, mechanisms of development and features of LIPPH while taking NSAIDs. A separate section is highlighted on the features of the management of such patients. In particular, in accordance with both domestic and foreign clinical guidelines for the drug genesis of liver damage, it is recommended to stop taking the inducer drug and prescribe ursodeoxycholic acid (UDCA). The efficacy of UDCA in patients with LIPCH, including those associated with the use of NSAIDs, has been confirmed by the results of a large number of randomized placebo-controlled clinical trials. Among the UDCA preparations on the market of the Russian Federation, one cannot fail to pay attention to Exho® (CJSC «Canonpharma Production»), which is bioequivalent to the reference drug, is produced in compliance with GMP standards on a high-tech production base, which ensures its quality, and an affordable price and a large the choice of dosage forms makes it possible to successfully use this drug, including in special categories of patients, for example, elderly patients and/or those suffering from dysphagia.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference127 articles.
1. Ofitsial'nyi sait Agentstva po kontrolyu bezopasnosti lekarstvennykh sredstv i produktsii meditsinskogo naznacheniya Novoi Zelandii Medsafe. Available at https://www.medsafe.govt.nz/profs/PUArticles/ AntibioticsSept2012.htm (data obrashcheniya: 20.06.2021). [The official website of the New Zealand Agency for the Safety of Medicines and Health Products Medsafe. Available at: https://www.medsafe.govt.nz/profs/PUArticles/AntibioticsSept2012.htm (accessed 02.26.2021). 2. Ivashkin V. T. Bolezni pecheni i zhelchevyvodyashchikh putei. Rukovodstvo dlya vrachei. 2-e izd. / V. T. Ivashkin. M.: ID M-Vesti, 2005. 536 s [Ivashkin V. T. Diseases of the liver and biliary tract. A guide for doctors. 2nd ed. V. T. Ivashkin / M.: ID M-Vesti. 2005. 536 p. (In Russ.)] 3. Ostapowicz G., Fontana R. J., Schiadt F. V., Larson A., Davern T. J., Han S. H., McCash-land T. M., Shakil A. O., Hay J, E., Hynan L., Cnppin J. S., Blei A. T., Samuel G., Reisch J., Lee W. M.; U. S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002 Dec 17; 137 (12): 947-54. https://doi.org/10.7326/0003-4819-137-12-200212170-00007. 4. Andrade R. J., Lucena M. I., Fernandez M. C., Pelaez G., Pachkoria K., Garcia-Ruiz E., Garcia-Munoz B., Gonzalez-Grande R., Pizarro A., Duran J. A., Jimenez M., Rodrigo L., Romero-Gomez M., Navarro J. M., Planas R., Costa J., Borras A., Soler A., Salmeron J., Martin-Vivaldi R.; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-in duced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005 Aug;129(2):512-21. Erratum in: Gas troenterology. 2005 Nov;129(5):1808. https://doi.org/10.1016/j.gastro.2005.05.006. 5. Chalasani N., Bonkovsky H. L., Fontana R., Lee W., Stolz A., TalwalkarJ., Reddy K. R., Watkins P. B., Navarro V., Barnhart H., Gu J., Serrano J.; United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015 Jun;148(7):1340-52. e7. doi: 10.1053/j.gastro.2015.03.006.
|
|